You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Medtronic

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Guerbet Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for GUERBET, and what generic and branded alternatives to GUERBET drugs are available?

GUERBET has four approved drugs.



Summary for Guerbet
US Patents:0
Tradenames:5
Ingredients:4
NDAs:4
Drug Master File Entries: 1

Drugs and US Patents for Guerbet

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-001 Mar 20, 2013 AP RX Yes Yes   Start Trial   Start Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 DISCN No No   Start Trial   Start Trial
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-003 Mar 20, 2013 AP RX Yes Yes   Start Trial   Start Trial
Guerbet LIPIODOL ethiodized oil OIL;INTRALYMPHATIC, INTRAUTERINE 009190-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial
Guerbet OXILAN-300 ioxilan INJECTABLE;INJECTION 020316-001 Dec 21, 1995 DISCN No No   Start Trial   Start Trial
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-002 Mar 20, 2013 AP RX Yes Yes   Start Trial   Start Trial
Guerbet OXILAN-350 ioxilan INJECTABLE;INJECTION 020316-002 Dec 21, 1995 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Guerbet

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Guerbet OXILAN-300 ioxilan INJECTABLE;INJECTION 020316-001 Dec 21, 1995 4,954,348   Start Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 4,014,986   Start Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 4,065,553   Start Trial
Guerbet OXILAN-350 ioxilan INJECTABLE;INJECTION 020316-002 Dec 21, 1995 4,954,348   Start Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 4,094,966   Start Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 4,065,554   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Mallinckrodt
Merck
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.